Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aim: To assess the efficacy of exenatide (EXE) once weekly + dapagliflozin once daily (DAPA) versus each drug alone in reducing biomarkers of fatty liver/steatosis and fibrosis in a post hoc analysis of DURATION‐8, a 104‐week study in 695 patients with type 2 diabetes uncontrolled by metformin monotherapy. Materials and methods: We evaluated the impact of the study treatments on non‐invasive markers of hepatic steatosis (fatty liver index [FLI] and non‐alcoholic fatty liver disease [NAFLD] liver fat score), fibrosis (fibrosis‐4 index [FIB‐4]) and severe fibrosis (NAFLD fibrosis score), along with liver enzymes and insulin resistance, at weeks 28 and 52. All outcomes in this analysis were exploratory, with nominal P values reported. Results: At week 28, biomarkers of fatty liver/steatosis and fibrosis were reduced from baseline in all treatment groups. At week 28, EXE once weekly + DAPA effects for decrease in FLI were stronger than those of EXE once weekly + placebo (PLB; −2.92, 95% confidence interval [CI] −5.11, −0.73; P = 0.0092) or DAPA+PLB (−2.77 [95% CI −4.93, −0.62]; P = 0.0119), and stronger than those of EXE once weekly + PLB at week 52 (−3.23 [95% CI −5.79, −0.68]; P = 0.0134). FIB‐4 showed reduction versus baseline only in the EXE once weekly + DAPA group at both week 28 (−0.06 [95% CI −0.11, −0.01]; P = 0.0135) and week 52 (−0.05 [95% CI −0.09, −0.004]; P = 0.0308). Conclusions: The EXE once weekly + DAPA combination showed stronger effects than EXE once weekly + PLB or DAPA + PLB in ameliorating markers of hepatic steatosis and fibrosis in patients with type 2 diabetes. Prospective trials are needed to validate these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 6×
“Weight loss is the mainstay of NAFLD treatment,2 and it has been previously demonstrated that the extent of weight loss achieved by patients is directly proportional to reduced NAFLD activity score, NASH resolution and fibrosis regression.30 Moreover, the Diabetes Remission Clinical Trial (DiRECT) reported that a weig…”
BackgroundInfluentialNoninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570 · cited 2×
“These have an impact on all tissues, including skeletal muscle, β cells and the liver, and modify inflammatory responses as well as glucose and lipid metabolism, thus contributing to metabolic abnormalities.(24,26,33) In patients with NAFLD, increased”
BackgroundPortillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503 · cited 2×
“It has been estimated that 50% of people with type 2 diabetes have NAFLD despite exhibiting liver enzymes within normal ranges.(1) People with type 2 diabetes and NAFLD are at an increased risk of disease progression to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma.”
BackgroundTaylor, R., Al-Mrabeh, A., Zhyzhneuskaya, S., Peters, C., Barnes, A. C., Aribisala, B. S., Hollingsworth, K. G., Mathers, J. C., Sattar, N., & Lean, M. E. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.003 · Cited by 450
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449 · cited 1×
“with type 2 diabetes, but with the side effect of significant weight gain.(2,13) Evidence indicates that glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter-2 (SGLT2) inhibi-”
BackgroundEriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396 · cited 6×
“Weight loss is the mainstay of NAFLD treatment,2 and it has been previously demonstrated that the extent of weight loss achieved by patients is directly proportional to reduced NAFLD activity score, NASH resolution and fibrosis regression.30 Moreover, the Diabetes Remission Clinical Trial (DiRECT) reported that a weig…”
BackgroundInfluentialGastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285 · cited 4×
“Adipo-IR (ie, the impaired suppression of lipolysis in the presence of high insulin levels) plays a key role in the pathogenesis of NAFLD.24-27 Adipose tissue dysfunction affects both glucose and lipid metabolism by releasing proinflammatory adipokines and NEFA.24,26 These have an impact on all tissues, including skel…”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 23
- 10.1136/gutjnl-2017-313884 · DOI · Paper page
- 10.2337/dc19-S004 · DOI · Paper page
- 10.1111/dme.13540 · DOI
- 10.1186/1471-230X-6-33 · DOI · Paper page
- 10.1053/j.gastro.2009.06.005 · DOI · Paper page
- 10.1002/hep.21496 · DOI · Paper page
- 10.1016/j.cgh.2009.05.033 · DOI · Paper page
- 10.1016/S2213-8587(18)30154-2 · DOI · Paper page
- 10.1111/dom.13520 · DOI · Paper page
- 10.1111/hepr.13304 · DOI · Paper page
- 10.1016/j.diabres.2018.05.017 · DOI · Paper page
- 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
- 10.2337/dc18-0680 · DOI · Paper page
- Jabbour SA, 2018, DURATION‐8 randomised controlled trial 104‐week results—once‐weekly exenatide (ExQW) plus once‐daily dapagliflozin (DAPA) vs. ExQW or DAPA alone [ADA abstract 104‐LB], Diabetes, 67, LB29
- 10.3390/nu7115475 · DOI · Paper page
- 10.1002/hep.25539 · DOI · Paper page
- 10.1002/hep.28392 · DOI · Paper page
- Klem L, 1995, Reading and understanding multivariate statistics, 65
- Giugliano D, 2019, Preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta‐analysis of cardiovascular outcome trials and intensive glucose control trials, J Am Heart Assoc, 18, e012356, 10.1161/JAHA.119.012356 · DOI · Paper page
- 10.1053/j.gastro.2015.04.005 · DOI · Paper page
- 10.1016/S0618-8278(19)30119-7 · doi:10.1016/s0618-8278(19)30119-7
- 10.1007/s13300-017-0355-3 · DOI · Paper page
- 10.1111/liv.13480 · DOI · Paper page
Cited by
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“A combination of exenatide once weekly plus dapagliflozin once a day reduced biomarkers of liver steatosis and fibrosis in patients with T2DM uncontrolled by metformin monotherapy [191].”
BackgroundSGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Hepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
Self-citationGlucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0277 · Cited by 131
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Self-citationNovel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1
Metadata
- Authors
- Gastaldelli, A., Repetto, E., Guja, C., Hardy, E., Han, J., Jabbour, S. A., & Ferrannini, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-12-14
- Volume
- 22
- Issue
- 3
- Pages
- 393-403
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2985060283
- Cited by
- 82
- References
- 11
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- AstraZeneca (GPP3)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.